Anindita Das serves as an Assistant Professor at Pauley Heart Center, Division of Cardiology, Virginia Commonwealth University, Richmond, Va, USA. She received a Ph.D. degree from Jadavpur University, India, 1997, completed her B.S. degree in chemistry from University of Burdwan, India, 1985 and M.S. degree in biochemistry from University of Kalyani, India, 1988. She performed her postdoctoral training in University of Kentucky during 1998-2001, Ohio State University during 2001, and Virginia Commonwealth University during 2002-2007. Dr. Das’s current area of research is focused on myocardial ischemia-reperfusion injury and heart failure. Dr. Das’s major interest is developing novel pharmacological and genetic therapeutic approaches to reduce injury in the heart following myocardial ischemia (heart attacks). Her research goal is to identify the signaling mechanism involved in the cardioprotection mediated by phosphodiesterase-5 inhibitors or mTOR-inhibitor, rapamycin. She is mainly interested to identify the role of key signaling molecule such as protein kinase G (PKG) in pharmacological preconditioning which protects the heart following ischemia-reperfusion injury. Her work in this area has resulted in a Beginning Grant-in-Aid from the American Heart Association, Mid-Atlantic Affiliate in 2007. Dr Das also investigates the effect of FDA-approved and clinically safe phosphodiesterase-5 inhibitor, sildenafil on chemotherapeutic efficacy of doxorubicin in several cancers, including prostate cancer and breast cancer. She is studying the mechanism involved in enhanced antitumor efficacy of doxorubicin by sildenafil in different human cancers. She is a Member of American Heart Association and a Member of Editorial Board of Journal of Clinical and Experimental Cardiology of OMICS Publishing Group.
Biography Updated on 23 March 2011